PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
23.04%
R&D growth less than half of GNPX's 201.87%. David Dodd would verify if efficiency advantage is sustainable.
21.61%
G&A growth less than half of GNPX's 111.62%. David Dodd would verify if efficiency advantage is structural.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
22.65%
Operating expenses growth less than half of GNPX's 129.73%. David Dodd would verify sustainability.
22.65%
Total costs growth less than half of GNPX's 129.73%. David Dodd would verify sustainability.
No Data
No Data available this quarter, please select a different quarter.
3.49%
D&A growth less than half of GNPX's 49.36%. David Dodd would verify if efficiency is sustainable.
-23.08%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-22.65%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-58.12%
Other expenses reduction while GNPX shows 337.90% growth. Joel Greenblatt would examine advantage.
-23.20%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-23.20%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-16.67%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-22.50%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
5.52%
Share count reduction exceeding 1.5x GNPX's 61.57%. David Dodd would verify capital allocation.
0.56%
Diluted share reduction exceeding 1.5x GNPX's 61.46%. David Dodd would verify capital allocation.